A treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed. Ciltacabtagene autoleucel—also known by Carvykti—was tested in a clinical trial involving 419 patients with multiple myeloma, whose disease was not responsive to the current frontline drug lenalidomide, a chemotherapy medicine. Multiple myeloma affects a type of white blood cells called plasma cells, and can cause cascading harms to the bones, kidneys, and immune health. There is currently no cure, though progression can be stopped for...